Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 2
2011 5
2012 2
2013 2
2014 1
2015 2
2016 2
2017 10
2018 14
2019 19
2020 43
2021 40
Text availability
Article attribute
Article type
Publication date

Search Results

137 results
Results by year
Filters applied: . Clear all
Page 1
The role of inflammation in irritable bowel syndrome (IBS).
Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. Ng QX, et al. J Inflamm Res. 2018 Sep 21;11:345-349. doi: 10.2147/JIR.S174982. eCollection 2018. J Inflamm Res. 2018. PMID: 30288077 Free PMC article. Review.
Despite the global prevalence and disease burden of IBS, its underlying pathophysiology remains unclear. Inflammation may play a pathogenic role in IBS. ...This review thus aimed to discuss the body of evidence pertaining to the presence of mucosal inflammation in …
Despite the global prevalence and disease burden of IBS, its underlying pathophysiology remains unclear. Inflammation may play a path …
Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis.
Altobelli E, Del Negro V, Angeletti PM, Latella G. Altobelli E, et al. Nutrients. 2017 Aug 26;9(9):940. doi: 10.3390/nu9090940. Nutrients. 2017. PMID: 28846594 Free PMC article. Review.
Irritable bowel syndrome (IBS) affects 7-15% of the general population. A recently devised dietary approach consists of restricting foods with highly fermentable oligo-, di-, and monosaccharides, and polyols (FODMAPs), which can trigger and/or exacerbate IBS symptom …
Irritable bowel syndrome (IBS) affects 7-15% of the general population. A recently devised dietary approach consists of restricting f …
Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.
Mishima Y, Ishihara S. Mishima Y, et al. Int J Mol Sci. 2020 Nov 17;21(22):8664. doi: 10.3390/ijms21228664. Int J Mol Sci. 2020. PMID: 33212919 Free PMC article. Review.
Irritable bowel syndrome (IBS) is one of the most prevalent functional gastrointestinal disorders, and accumulating evidence gained in both preclinical and clinical studies indicate the involvement of enteric microbiota in its pathogenesis. ...Based on these results, the t …
Irritable bowel syndrome (IBS) is one of the most prevalent functional gastrointestinal disorders, and accumulating evidence gained i …
Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.
Lewis ED, Antony JM, Crowley DC, Piano A, Bhardwaj R, Tompkins TA, Evans M. Lewis ED, et al. Nutrients. 2020 Apr 21;12(4):1159. doi: 10.3390/nu12041159. Nutrients. 2020. PMID: 32326347 Free PMC article. Clinical Trial.
Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifido …
Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IB …
Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use.
Uranga JA, Martínez V, Abalo R. Uranga JA, et al. Molecules. 2020 Sep 20;25(18):4314. doi: 10.3390/molecules25184314. Molecules. 2020. PMID: 32962285 Free PMC article. Review.
One important feature of mast cells is that their population is usually increased in animal models and biopsies from patients with irritable bowel syndrome (IBS). Therefore, mast cells and mast cell mediators are regarded as key components in IBS pathophysiology. …
One important feature of mast cells is that their population is usually increased in animal models and biopsies from patients with irritable …
A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. Ishaque SM, et al. BMC Gastroenterol. 2018 May 25;18(1):71. doi: 10.1186/s12876-018-0788-9. BMC Gastroenterol. 2018. PMID: 29801486 Free PMC article. Clinical Trial.

RESULTS: Probiotic treatment significantly improved the severity of abdominal pain in patients with IBS-D. A 69% reduction for probiotic versus 47% for placebo (p < 0.001) equates to a 145 point reduction on the IBS-severity scoring system (IBS-SSS). ...In

…
RESULTS: Probiotic treatment significantly improved the severity of abdominal pain in patients with IBS-D. A 69% reduction for probio …
Expressive writing is a promising therapeutic modality for the management of IBS: a pilot study.
Halpert A, Rybin D, Doros G. Halpert A, et al. Am J Gastroenterol. 2010 Nov;105(11):2440-8. doi: 10.1038/ajg.2010.246. Epub 2010 Jun 15. Am J Gastroenterol. 2010. PMID: 20551938
OBJECTIVES: We sought to test the effectiveness of expressive writing about irritable bowel syndrome (IBS) on disease severity, IBS-related cognition (perceived control over the illness or adaptive cognition), and IBS-specific quality of life. METHODS: …
OBJECTIVES: We sought to test the effectiveness of expressive writing about irritable bowel syndrome (IBS) on disease severity …
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Chey WD, Lembo AJ, Rosenbaum DP. Chey WD, et al. Am J Gastroenterol. 2020 Feb;115(2):281-293. doi: 10.14309/ajg.0000000000000516. Am J Gastroenterol. 2020. PMID: 31934897 Free PMC article. Clinical Trial.
This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 3, double-blind study (ClinicalTrials.gov identifier NCT02621892), patients wi …
This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant ir …
Intestinal microbiota in functional bowel disorders: a Rome foundation report.
Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Simrén M, et al. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22. Gut. 2013. PMID: 22730468 Free PMC article.
Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host-microbial interactions in IBS. ...The authors …
Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut …
137 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page